Search PubMedSearch

PubMed · 2190179

T cell adhesion.

Abstract

Antigen recognition by the T cell receptor cannot ensure by its own T cell activation. Other membranes molecules are required in order to achieve transient but strong adhesion of the T cell to the antigen presenting cell. Two main molecular adhesion pathways have been characterized involving the CD2 molecule binding the LFA-3 molecule and the LFA-1 molecule binding the ICAM-1 or ICAM-2 molecule. These results have been provided by the use of the three approaches, i-e inhibition of T cell activation and adhesion by monoclonal antibodies, the study of the adhesion of lymphocytes that do not express one or several adhesion molecules and finally the demonstration that the transfection of gene(s) coding for adhesion molecules into fibroblasts cotransfected with HLA molecules make the latter cells able to present antigen(s). The importance of the concept of antigen-independent T cell adhesion has been further underlined by in vivo use of monoclonal antibodies specific for adhesion molecule(s): LFA-1. Such antibody can efficiently block rejection of HLA non identical bone marrow in children. This opens further prospect of immunosuppression through blocking of T cell adhesion.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A Fischer. 1990. T cell adhesion.. https://pubmed.ncbi.nlm.nih.gov/2190179/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma.

In glioblastoma (GBM), the most frequent and lethal brain tumor, therapies suppressing recurrently altered signaling pathways failed to extend survival. However, in patient subsets, specific genetic lesions can confer sensitivity to targeted agents. By exploiting an integrated model based on patient-derived stem-like cells, faithfully recapitulating the original GBMs in vitro and in vivo, here, we identify a human GBM subset (∼9% of all GBMs) characterized by ERBB3 overexpression and nuclear accumulation. ERBB3 overexpression is driven by inheritable promoter methylation or post-transcriptional silencing of the oncosuppressor miR-205 and sustains the malignant phenotype. Overexpressed ERBB3 behaves as a specific signaling platform for fibroblast growth factor receptor (FGFR), driving PI3K/AKT/mTOR pathway hyperactivation, and overall metabolic upregulation. As a result, ERBB3 inhibition by specific antibodies is lethal for GBM stem-like cells and xenotransplants. These findings highlight a subset of patients eligible for ERBB3-targeted therapy.

Antibodies

The yeast SEN1 gene is required for the processing of diverse RNA classes.

A single base change in the helicase superfamily 1 domain of the yeast Saccharomyces cerevisiae SEN1 gene results in a heat-sensitive mutation that alters the cellular abundance of many RNA species. We compared the relative amounts of RNAs between cells that are wild-type and mutant after temperature-shift. In the mutant several RNAs were found to either decrease or increase in abundance. The affected RNAs include tRNAs, rRNAs and small nuclear and nucleolar RNAs. Many of the affected RNAs have been positively identified and include end-matured precursor tRNAs and the small nuclear and nucleolar RNAs U5 and snR40 and snR45. Several small nucleolar RNAs co-immunoprecipitate with Sen1 but differentially associate with the wild-type and mutant protein. Its inactivation also impairs precursor rRNA maturation, resulting in increased accumulation of 35S and 6S precursor rRNAs and reduced levels of 20S, 23S and 27S rRNA processing intermediates. Thus, Sen1 is required for the biosynthesis of various functionally distinct classes of nuclear RNAs. We propose that Sen1 is an RNA helicase acting on a wide range of RNA classes. Its effects on the targeted RNAs in turn enable ribonuclease activity.

Antibodies